Peter Sjö

Peter Sjö is Head of Drug Discovery Programme. He joined DNDi in March 2018 as Discovery Project Leader.

Peter has more than 24 years of experience from drug discovery at AstraZeneca R&D in Sweden, first at the former site in Lund and more recently at the research site in Gothenburg. Most of his career he has worked in the respiratory and inflammation disease areas discovering new drugs for the treatment of chronic diseases such as asthma and chronic obstructive pulmonary disease (COPD). At AstraZeneca, Peter held multiple positions as both project leader and line manager. Since 2011 he has lead the Medicinal Chemistry Department in the respiratory disease area at the AstraZeneca Gothenburg site, delivering 7 novel candidate compounds into clinical development. During 2015-2016 he made a 6 months sabbatical, working at the Medicines for Malaria Venture in Geneva.

Peter holds a PhD in synthetic organic chemistry from University of Oslo 1993 on the topic of synthesis of enantiopure muscarinic antagonists. Research interests are in the area of medicinal chemistry in particular on the design of novel nuclear hormone receptor modulators, kinase, and protease inhibitors.